End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
31.3 CNY | +1.52% | -6.26% | -15.97% |
04-26 | Winner Medical's Q1 Profit Drops 52% as Operating Income Slides 19% | MT |
04-26 | Winner Medical's 2023 Profit Shrinks 65%, Operating Income Falls 28% | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by -100% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.97% | 2.52B | C+ | ||
+11.84% | 27.79B | B+ | ||
-32.46% | 2.98B | B- | ||
+11.90% | 2.34B | - | A- | |
-1.11% | 1.91B | B | ||
-7.78% | 1.39B | B | ||
-0.38% | 1.27B | - | ||
+5.15% | 1.13B | - | ||
+13.51% | 1.12B | C | ||
-2.06% | 1.02B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300888 Stock
- Ratings Winner Medical Co., Ltd.